Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is now a licensed oral alternative to weight loss injections in the UK. Wegovy tablets — oral semaglutide — were approved by the MHRA on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine specifically for weight management. So if the idea of a weekly injection has been the thing stopping you from starting, this changes the conversation. Both the tablet and the injection contain the same active medicine, semaglutide, and both are prescription-only medicines: a prescriber must assess your circumstances before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer: it is not a different medicine, it is the same GLP-1 active ingredient, semaglutide, reformulated so it can be absorbed through the gut wall. Wegovy injection delivers semaglutide under the skin once a week via a pre-filled pen. Wegovy tablets deliver semaglutide once a day by mouth, combined with an absorption enhancer called SNAC that protects the molecule as it passes through the stomach.
Both work by activating the GLP-1 receptor, a pathway involved in appetite regulation and feelings of fullness. Gastric emptying slows, hunger signals quieten, and most people find they eat less without having to fight cravings consciously. The mechanism is the same; the route into the body differs. If you are trying to decide which format suits you, our guide to weight loss pills versus injections walks through the practical differences in detail, going well beyond the question of needles versus tablets.
The MHRA licensed Wegovy tablets for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure or raised cholesterol. That eligibility sits alongside a reduced-calorie diet and increased physical activity, the medicine works with lifestyle changes, not instead of them. The NHS patient page on semaglutide covers the pharmacology and licensed uses in plain terms and is a good first read.
Broadly, yes, though the headline numbers differ slightly by trial. The OASIS 4 phase 3 trial (307 adults, 64 weeks, placebo-controlled, participants without type 2 diabetes) found an average weight reduction of around 13.6% with the tablet versus around 2.4% with placebo. Among people who stayed fully adherent to treatment throughout the trial, the figure reached approximately 17%. Those two numbers answer different questions: 13.6% is the real-world average across everyone who took the tablet; 17% is what happened when people took every dose as prescribed. Both are meaningful, but the lower figure is the honest planning number.
The Wegovy injection at its 2.4 mg maintenance dose produced around 15% average weight loss over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. A higher 7.2 mg dose of the injection, approved by the MHRA in January 2026 and available as a dedicated single-dose pen from April 2026, has reported around 20.7% average loss in trials. So the tablet sits between the standard injection dose and the higher one, a credible result, and notable given that oral absorption of large molecules like semaglutide was considered near-impossible until recently.
The most common side effects reported in the OASIS 4 trial were gastrointestinal: nausea, diarrhoea, constipation and vomiting, affecting around 74% of tablet users versus 42% in the placebo group. These were generally mild to moderate and tended to settle as the body adjusted. The injection's side effect profile is similar in character, which makes sense given the shared mechanism.
The dosing schedule runs from 1.5 mg once daily, escalating through 4 mg and 9 mg to a 25 mg maintenance dose, with at least one month at each level before moving up. The prescriber guides that progression based on how you are tolerating the medicine. People already established on the 2.4 mg weekly injection may move directly to the 25 mg tablet under clinical guidance, they do not restart from scratch.
The tablet must be taken first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120 ml). You then wait at least 30 minutes before any food, drink (including coffee) or other oral medicines. That 30-minute window is not optional: food and drink significantly reduce absorption. It is a habit that takes some getting used to, but many people fold it into an existing morning routine without much friction, set it on the bedside table the night before, swallow it before the kettle goes on.
Storage is simpler than the injection. No refrigeration. The tablets keep at room temperature, which also makes them considerably easier to travel with. If you want to understand how the two formats stack up on cost and practicality, our page on weight loss injection costs in the UK gives useful context, and the pill versus injection comparison covers the practical differences side by side.
Wegovy tablets are not currently available on the NHS. A NICE technology appraisal would be required before NHS commissioning could begin, and that process takes time. The injection (Wegovy) is available via specialist NHS weight management services under NICE technology appraisal TA875, but waiting times in many areas are long, and the eligibility criteria are specific. For the tablet, private prescription is the only route right now.
A legitimate private prescription requires a clinical assessment, a prescriber reviews your BMI, medical history, current medicines and any contraindications before issuing a prescription. That is not a formality; it is what keeps the medicine safe. Anyone offering semaglutide tablets without that step is operating outside the law. You can verify any online pharmacy on the GPhC pharmacy register before handing over payment or personal details, it takes thirty seconds and is the single most useful check you can do.
If you are weighing up whether the tablet or the injection suits your situation better, that is exactly the kind of question a prescriber should answer with you rather than you deciding alone. Thinking through which format fits your life is a good starting point, and our clinical team can take it from there. Starting a free consultation with nume (sorry, with our team at nume) means a GPhC-registered Independent Prescriber reads your answers the same day, not software. If you are clinically suitable, treatment is dispatched the same working day for next-day delivery. Some people time their first order around payday or the start of a new week to make the routine feel like a fresh beginning, and if you are still deciding whether a pill or an injection is the right fit, our page on whether a weight loss pill can replace an injection may help you land on an answer before your first consultation. There is no wrong moment, as long as the clinical picture is right.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.